Who
Nancy Stagliano
Director
Company insider
Files Form 4 as: Director, Electra Therapeutics; Director, Pandion Therapeutics.
In numbers
- Trades disclosed
- 13
- Buys
- 1
- Sells
- 0
- Bought
- $18K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 17 Jul 2020
- Last trade
- 21 Sep 2026
- Last filed
- 21 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Sep 2026filed 21 Sep 2026 | ETRA Electra TherapeuticsBiotechnology | SEC FORM 4 Code C | —255,635 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ETRA Electra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —255,635 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ETRA Electra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —255,635 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ETRA Electra TherapeuticsBiotechnology | SEC FORM 4 Code C | —255,635 | filing |
| 1 Apr 2021filed 1 Apr 2021 | Pandion Therapeuticsoption or derivative | SEC FORM 4 Code D | —17,671 | filing |
| 1 Apr 2021filed 1 Apr 2021 | Pandion Therapeutics | SEC FORM 4 Code U | $60K1,000 at $60.00 | filing |
| 1 Apr 2021filed 1 Apr 2021 | Pandion Therapeutics | SEC FORM 4 Code U | $4.4M73,067 at $60.00 | filing |
| 21 Jul 2020filed 21 Jul 2020 | Pandion Therapeuticsoption or derivative | SEC FORM 4 Code C | —28,620 at $0.00 | filing |
| 21 Jul 2020filed 21 Jul 2020 | Pandion Therapeuticsoption or derivative | SEC FORM 4 Code C | —47,898 at $0.00 | filing |
| 21 Jul 2020filed 21 Jul 2020 | Pandion Therapeutics | SEC FORM 4 Code C | —15,004 | filing |
| 21 Jul 2020filed 21 Jul 2020 | Pandion Therapeutics | SEC FORM 4 Bought | $18K1,000 at $18.00 | filing |
| 17 Jul 2020filed 21 Jul 2020 | Pandion Therapeuticsoption or derivative | SEC FORM 4 Code A | —3,674 at $0.00 | filing |
| 17 Jul 2020filed 21 Jul 2020 | Pandion Therapeuticsoption or derivative | SEC FORM 4 Code A | —13,997 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.